Glucophage Xr

Diabetic Ketoacidosis, Congestive Heart Failure, Type 1 Diabetes + 16 more
Treatment
21 FDA approvals
20 Active Studies for Glucophage Xr

What is Glucophage Xr

MetforminThe Generic name of this drug
Treatment SummaryMetformin is a medication used to treat type II diabetes. It works by decreasing blood sugar levels without causing hypoglycemia. Metformin also helps to reduce insulin resistance and reduces fasting insulin levels. This medication can also help with weight loss in obese people with type II diabetes. It was first approved in Canada in 1972 and in the US in 1995 and is available in regular or extended-release forms.
Metformin Hydrochlorideis the brand name
image of different drug pills on a surface
Glucophage Xr Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Metformin Hydrochloride
Metformin
2002
1263

Approved as Treatment by the FDA

Metformin, otherwise known as Metformin Hydrochloride, is approved by the FDA for 21 uses which include Type 2 Diabetes Mellitus and Ejection fraction decreased .
Type 2 Diabetes Mellitus
Used to treat Type 2 Diabetes Mellitus in combination with Dapagliflozin
Ejection fraction decreased
Used to treat Ejection fraction decreased in combination with Dapagliflozin
Type 2 Diabetes
Used to treat Type 2 Diabetes Mellitus in combination with Dapagliflozin
Chronic Kidney Disease
Used to treat Chronic Kidney Disease (CKD) in combination with Dapagliflozin
Renal Insufficiency
Used to treat decreased estimated glomerular filtration rate in combination with Dapagliflozin
Heart Failure
Used to treat NYHA Functional Class II-IV Heart Failure in combination with Dapagliflozin
Kidney Failure
Used to treat End Stage Renal Disease (ESRD) in combination with Dapagliflozin
Ketosis
Used to treat Diabetic Ketoacidosis in combination with Saxagliptin
Diet
Used to treat Diet in combination with Dapagliflozin
Hospitalizations
Used to treat Hospitalizations in combination with Dapagliflozin
Congestive Heart Failure
Used to treat Heart Failure in combination with Dapagliflozin
Physical Activity
Used to treat Exercise in combination with Dapagliflozin
Chronic Kidney Disease (CKD)
Used to treat Chronic Kidney Disease (CKD) in combination with Dapagliflozin
Type 1 Diabetes Mellitus
Used to treat Type 1 Diabetes Mellitus in combination with Sitagliptin
Diabetic Ketoacidosis
Used to treat Diabetic Ketoacidosis in combination with Saxagliptin
Cardiovascular Mortality
Used to treat Cardiovascular Mortality in combination with Dapagliflozin
Diabetes Mellitus
Used to treat uncontrolled diabetes in combination with Rosiglitazone
Cardiovascular Disease
Used to treat Cardiovascular Risk in combination with Dapagliflozin
Cardiovascular Diseases
Used to treat established cardiovascular disease in combination with Dapagliflozin
Heart failure
Used to treat Heart Failure in combination with Dapagliflozin
Type 1 Diabetes
Used to treat Type 1 Diabetes Mellitus in combination with Sitagliptin

Effectiveness

How Glucophage Xr Affects PatientsInsulin helps to keep your blood glucose levels in balance. People with type 2 diabetes have a harder time processing insulin, which can cause their blood sugar levels to be too high. Metformin helps by decreasing the amount of glucose your liver makes, slowing down how much glucose is absorbed by your body, and making it easier for insulin to work. Metformin does not cause too much insulin to be released like some other diabetes treatments do. In a study, people taking metformin for 29 weeks had their fasting plasma glucose (blood sugar levels when not eating) drop by an average of 59 mg/dL, while those taking a
How Glucophage Xr works in the bodyMetformin works to lower blood sugar levels by decreasing the amount of sugar produced in the liver, reducing the amount of sugar absorbed from food, and improving the body’s sensitivity to insulin. Specifically, metformin accumulates in cells and the mitochondria, and inhibits a molecule called mitochondrial complex I. This prevents ATP production, leading to an increase in AMP:ATP ratios. This activates an enzyme called AMP-activated protein kinase (AMPK), which helps regulate glucose metabolism. Metformin also inhibits _fructose-1,6-bisphosphatase_ and adenylate cyclase

When to interrupt dosage

The portion of Glucophage Xr is dependent upon the recognized condition, including Diet, insufficient answer to metformin and Diabetic Ketoacidosis. The measure fluctuates according to the strategy of delivery (e.g. Oral or Tablet - Oral) indicated in the table beneath.
Condition
Dosage
Administration
Renal Insufficiency
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
inadequate response to metformin
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Insulin Resistance
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Cardiovascular Diseases
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Diabetes Mellitus
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Congestive Heart Failure
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Type 2 Diabetes
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Chronic Kidney Disease
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Diabetic Ketoacidosis
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Physical Activity
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Kidney Failure
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Diet
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Hospitalizations
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Heart Failure
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Type 1 Diabetes
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Polycystic Ovarian Syndrome
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Cardiovascular Disease
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Cardiovascular Mortality
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Ejection fraction decreased
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Warnings

Glucophage Xr has twenty contraindications, hence it should not be consumed for the situations indicated in the following table.Glucophage Xr Contraindications
Condition
Risk Level
Notes
Liver Failure
Do Not Combine
Renal Insufficiency
Do Not Combine
Heart Arrest
Do Not Combine
Diabetic Ketoacidosis
Do Not Combine
Operative Surgery
Do Not Combine
Metabolic acidosis
Do Not Combine
Heart Failure
Do Not Combine
Renal Insufficiency
Do Not Combine
kidney function unknown
Do Not Combine
Hypovolemic Shock
Do Not Combine
serum creatinine above upper limit for age range
Do Not Combine
ethanol
Do Not Combine
Acute Coryza
Do Not Combine
Hypoxemia
Do Not Combine
Liver Failure
Do Not Combine
Acidosis, Lactic
Do Not Combine
Diabetic Ketoacidosis
Do Not Combine
Renal Insufficiency
Do Not Combine
Renal Insufficiency, Chronic
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Metformin may interact with Pulse Frequency
There are 20 known major drug interactions with Glucophage Xr.
Common Glucophage Xr Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Metformin.
Procainamide
Major
The excretion of Procainamide can be decreased when combined with Metformin.
Topotecan
Major
The excretion of Topotecan can be decreased when combined with Metformin.
Abacavir
Minor
Metformin may decrease the excretion rate of Abacavir which could result in a higher serum level.
Aclidinium
Minor
Metformin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Glucophage Xr Toxicity & Overdose RiskThe toxic dose of metformin in rats is 1g/kg when taken orally, 500mg/kg when taken intraperitoneally, and 300mg/kg when taken subcutaneously. The toxic dose in mice is 1450 mg/kg when taken orally, 420 mg/kg when taken intraperitoneally, and 225 mg/kg when taken subcutaneously. Taking too much metformin may increase the risk of lactic acidosis, which is characterized by high blood lactate levels, anion gap acidosis, and an increased lactate:pyruvate ratio. Risk factors for l
image of a doctor in a lab doing drug, clinical research

Glucophage Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Glucophage Xr?

Currently, there are 346 active studies investigating the capacity of Glucophage XR to treat Type 2 Diabetes, Type 1 Diabetes, and lack of response to metformin.
Condition
Clinical Trials
Trial Phases
Chronic Kidney Disease
102 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1
Cardiovascular Diseases
0 Actively Recruiting
Congestive Heart Failure
186 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1
Type 1 Diabetes
183 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4
Cardiovascular Disease
27 Actively Recruiting
Not Applicable, Early Phase 1, Phase 3, Phase 2
Type 2 Diabetes
167 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Kidney Failure
40 Actively Recruiting
Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
Physical Activity
24 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Insulin Resistance
0 Actively Recruiting
Renal Insufficiency
0 Actively Recruiting
Cardiovascular Mortality
0 Actively Recruiting
Ejection fraction decreased
0 Actively Recruiting
Hospitalizations
1 Actively Recruiting
Not Applicable
Diabetic Ketoacidosis
2 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Polycystic Ovarian Syndrome
6 Actively Recruiting
Not Applicable, Phase 1
inadequate response to metformin
0 Actively Recruiting
Heart Failure
0 Actively Recruiting
Diet
5 Actively Recruiting
Not Applicable, Phase 1
Diabetes Mellitus
0 Actively Recruiting

Glucophage Xr Reviews: What are patients saying about Glucophage Xr?

5Patient Review
8/28/2010
Glucophage Xr for Type 2 Diabetes Mellitus
I have been taking the generic form for months and have suffered diarrhea to the point that I'm leary of going out. It strikes fast and furious. I have been recently switched to Glucophage XR 500mg 2 2 times daily and it has calmed down. Problem, insurance won't pay for it and it's too expensive to buy.
5Patient Review
9/13/2010
Glucophage Xr for Type 2 Diabetes Mellitus
I found this medication very easy to use and it gave me good control over my blood sugar levels.
5Patient Review
6/13/2012
Glucophage Xr for Type 2 Diabetes Mellitus
This medication didn't have a huge impact on my blood sugar, but I did notice that while I was taking a break from it (for a CAT scan), my urinary incontinence disappeared. My doctor and I decided that it wasn't worth the tradeoff, so I stopped taking the drug and am now focusing on diet instead. So far, so good!
5Patient Review
5/4/2010
Glucophage Xr for Type 2 Diabetes Mellitus
This medication sometimes gives me diarrhea, but I've also found that it increases my sex drive. I would recommend reading the leaflet from the pharmacy before starting this medication, as it contains a lot of useful information.
4.7Patient Review
6/27/2010
Glucophage Xr for Type 2 Diabetes Mellitus
I've been on this medication for about a week. Unfortunately, I often wake up in the middle of the night to vomit and/or have diarrhea. I'm not sure if the cure is worse than the disease at this point.
4.7Patient Review
1/18/2015
Glucophage Xr for Type 2 Diabetes Mellitus
I've been finding these tablets in my stool for a few months now. They don't seem to be digesting properly in my stomach. I'm also on insulin with the Glucophage. My doctor prescribed it like this. I've been diabetic type 1 for 16 years. Should I stop taking them? I did for 2 days and felt that my sugar levels stayed high.
4Patient Review
11/24/2010
Glucophage Xr for Type 2 Diabetes Mellitus
This medication caused me to have lots of loose bowels.
4Patient Review
3/4/2009
Glucophage Xr for Type 2 Diabetes Mellitus
3.3Patient Review
9/28/2016
Glucophage Xr for Prevention of Type 2 Diabetes Mellitus
I've been taking 500mg of this medication for eight months and have experienced several negative side effects, including bloating, loss of appetite, constipation, and weight loss.
3.3Patient Review
1/7/2011
Glucophage Xr for Prevention of Type 2 Diabetes Mellitus
After taking my 1500mg dose of this medication, I had a bowel movement and found two orange tablets in my stool. These were the size of the glucophage pills. Should I discontinue the medication? My fasting blood sugar is no higher than 118 and my HgbA1C is 5.4%.
3Patient Review
11/2/2009
Glucophage Xr for Type 2 Diabetes Mellitus
2.7Patient Review
10/26/2010
Glucophage Xr for Type 2 Diabetes Mellitus
Sometimes I experience severe diarrhea, but since combining this medication with diamicron, I have been doing much better.
2.7Patient Review
8/15/2011
Glucophage Xr for Prevention of Type 2 Diabetes Mellitus
I got severe diarrhea.
2.7Patient Review
8/5/2011
Glucophage Xr for Type 2 Diabetes Mellitus
So far, so good.
2.3Patient Review
9/23/2013
Glucophage Xr for Type 2 Diabetes Mellitus
I was hesitant to go on medication, but after a year of trying to control my blood sugar with diet alone and seeing little results, I decided to give it a try. I started taking 2000mg of Metformin XR daily, in two 500mg doses with breakfast and dinner. The results were remarkable – my blood sugar has been consistently between 100 and 125, and I've been able to add back nutritious foods to my diet. There were some mild side effects at first – nausea, bloating, gas, and belching – but they mostly went away after a week. Overall, I wish I had done this sooner
1.7Patient Review
6/8/2012
Glucophage Xr for Type 2 Diabetes Mellitus
I felt nauseous and bloated when I first started taking this medication, but reducing the dosage helped. After a few days on a lower dose, I was able to increase it again and have been feeling better for the past two weeks.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about glucophage xr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between metformin and Glucophage XR?

"Metformin ER is a drug used to treat type 2 diabetes. It is the extended-release version of metformin and only needs to be taken once daily with food. The maximum total daily dose of metformin ER is 2000 mg. Metformin ER is only indicated for adults with type 2 diabetes."

Answered by AI

How quickly does Glucophage XR work?

"results are usually seen within 2 days of taking the medication, however timing varies depending on dosage. other diabetes medication work to increase insulin in the body, which can work faster to lower blood sugar levels."

Answered by AI

What is Glucophage XR used for?

"This medication is used to treat type 2 diabetes. By controlling high blood sugar levels, it helps to prevent damage to the kidneys, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also reduce your risk of having a heart attack or stroke."

Answered by AI

What are the side effects of Glucophage XR?

"Strong or unusual muscle pain, feeling cold, difficulty breathing, feeling dizzy or lightheaded, feeling very tired or weak, stomach pain, or vomiting, or a slow or irregular heart rate may be signs that something is wrong."

Answered by AI

Clinical Trials for Glucophage Xr

Image of Stanford University in Palo Alto, United States.

Decision Support Tool for Type 1 Diabetes

18 - 60
All Sexes
Palo Alto, CA
This study evaluates a digital decision-support tool designed to help individuals with type 1 diabetes prepare for exercise. This netIOB \& Exercise Tool (NEXT) uses glucose data and insulin delivery history to recommend individualized strategies such as carbohydrate intake, insulin adjustments, or delays in exercise start time. Participants will complete three structured aerobic or mixed-exercise sessions using different guidance approaches: (A) published consensus-based standard-of-care guidelines (B) usual personal care routines (C) the NEXT tool The study compares glucose outcomes, safety, and carbohydrate use across these conditions to inform better exercise preparation and support tools for people with diabetes.
Waitlist Available
Has No Placebo
Stanford UniversityRayhan Lal, MD
Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Image of New York University Langone Health in New York, United States.

GGTA1 KO Thymokidney for Kidney Failure

40 - 70
All Sexes
New York, NY
The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow-up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, GGTA1 KO Thymokidney survival, and screening for zoonotic infections. Part B will continue for the lifetime of the participant or for 52 weeks following nephrectomy, if required.
Phase 1 & 2
Recruiting
New York University Langone HealthUnited Therapeutics
Have you considered Glucophage Xr clinical trials? We made a collection of clinical trials featuring Glucophage Xr, we think they might fit your search criteria.Go to Trials
Image of Medpace Clinical Pharmaology Unit in Cincinnati, United States.

PATAS for Type 2 Diabetes

18 - 55
All Sexes
Cincinnati, OH
The primary objective of Part 1 of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of Part 1 of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 of this study are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. The secondary objectives of Part 2 of this study are to evaluate the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers; and to characterize the adverse event (AE) profiles of the various dose levels of PATAS.
Phase 1
Waitlist Available
Medpace Clinical Pharmaology UnitVincent Marion, Ph.D.AdipoPharma LLC
Have you considered Glucophage Xr clinical trials? We made a collection of clinical trials featuring Glucophage Xr, we think they might fit your search criteria.Go to Trials
Image of The Worship Center Cristian Church in Birmingham, United States.

Black Impact for Heart Health

18+
Male
Birmingham, AL
The goal of this clinical trial is to evaluate the implementation and effectiveness of the Black Impact program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the Black Impact program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the Black Impact program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.
Waitlist Available
Has No Placebo
The Worship Center Cristian Church
Have you considered Glucophage Xr clinical trials? We made a collection of clinical trials featuring Glucophage Xr, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security